vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and IDEX Corporation (IEX). Click either name above to swap in a different company.
IDEX Corporation is the larger business by last-quarter revenue ($398.4M vs $281.3M, roughly 1.4× Guardant Health, Inc.). IDEX Corporation runs the higher net margin — 30.1% vs -45.7%, a 75.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 16.7%). IDEX Corporation produced more free cash flow last quarter ($86.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -29.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
GH vs IEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $398.4M |
| Net Profit | $-128.5M | $120.0M |
| Gross Margin | 64.6% | 99.9% |
| Operating Margin | -43.0% | 43.3% |
| Net Margin | -45.7% | 30.1% |
| Revenue YoY | 39.4% | 16.7% |
| Net Profit YoY | -15.8% | 25.7% |
| EPS (diluted) | $-1.01 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $281.3M | $899.1M | ||
| Q3 25 | $265.2M | $878.7M | ||
| Q2 25 | $232.1M | $865.4M | ||
| Q1 25 | $203.5M | $814.3M | ||
| Q4 24 | $201.8M | $862.9M | ||
| Q3 24 | $191.5M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $-128.5M | $128.3M | ||
| Q3 25 | $-92.7M | $127.8M | ||
| Q2 25 | $-99.9M | $131.6M | ||
| Q1 25 | $-95.2M | $95.5M | ||
| Q4 24 | $-111.0M | $123.2M | ||
| Q3 24 | $-107.8M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | 64.6% | 43.1% | ||
| Q3 25 | 64.7% | 44.5% | ||
| Q2 25 | 65.0% | 45.3% | ||
| Q1 25 | 63.3% | 45.3% | ||
| Q4 24 | 61.6% | 42.5% | ||
| Q3 24 | 61.1% | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | -43.0% | 20.4% | ||
| Q3 25 | -37.3% | 21.1% | ||
| Q2 25 | -45.9% | 21.7% | ||
| Q1 25 | -54.6% | 17.4% | ||
| Q4 24 | -62.4% | 19.2% | ||
| Q3 24 | -61.3% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | -45.7% | 14.3% | ||
| Q3 25 | -35.0% | 14.5% | ||
| Q2 25 | -43.0% | 15.2% | ||
| Q1 25 | -46.8% | 11.7% | ||
| Q4 24 | -55.0% | 14.3% | ||
| Q3 24 | -56.3% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $-1.01 | $1.71 | ||
| Q3 25 | $-0.74 | $1.70 | ||
| Q2 25 | $-0.80 | $1.74 | ||
| Q1 25 | $-0.77 | $1.26 | ||
| Q4 24 | $-0.90 | $1.61 | ||
| Q3 24 | $-0.88 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $586.2M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $4.0B |
| Total Assets | $2.0B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $378.2M | $580.0M | ||
| Q3 25 | $580.0M | $593.8M | ||
| Q2 25 | $629.1M | $568.2M | ||
| Q1 25 | $698.6M | $594.1M | ||
| Q4 24 | $525.5M | $620.8M | ||
| Q3 24 | $585.0M | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $1.8B | ||
| Q3 25 | $1.1B | $1.9B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.1B | $2.0B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | — | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $-99.3M | $4.0B | ||
| Q3 25 | $-354.5M | $4.0B | ||
| Q2 25 | $-305.5M | $4.0B | ||
| Q1 25 | $-250.8M | $3.9B | ||
| Q4 24 | $-139.6M | $3.8B | ||
| Q3 24 | $-60.1M | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $2.0B | $6.9B | ||
| Q3 25 | $1.3B | $7.0B | ||
| Q2 25 | $1.3B | $6.9B | ||
| Q1 25 | $1.3B | $6.8B | ||
| Q4 24 | $1.5B | $6.7B | ||
| Q3 24 | $1.5B | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | $86.0M |
| FCF MarginFCF / Revenue | -19.3% | 21.6% |
| Capex IntensityCapex / Revenue | 9.9% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $209.5M | ||
| Q3 25 | $-35.4M | $203.5M | ||
| Q2 25 | $-60.3M | $161.7M | ||
| Q1 25 | $-62.7M | $105.7M | ||
| Q4 24 | $-64.5M | $172.6M | ||
| Q3 24 | $-51.1M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $-54.2M | $189.8M | ||
| Q3 25 | $-45.8M | $188.7M | ||
| Q2 25 | $-65.9M | $146.9M | ||
| Q1 25 | $-67.1M | $91.4M | ||
| Q4 24 | $-83.4M | $157.1M | ||
| Q3 24 | $-55.3M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | -19.3% | 21.1% | ||
| Q3 25 | -17.3% | 21.5% | ||
| Q2 25 | -28.4% | 17.0% | ||
| Q1 25 | -33.0% | 11.2% | ||
| Q4 24 | -41.3% | 18.2% | ||
| Q3 24 | -28.9% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 9.9% | 2.2% | ||
| Q3 25 | 3.9% | 1.7% | ||
| Q2 25 | 2.4% | 1.7% | ||
| Q1 25 | 2.2% | 1.8% | ||
| Q4 24 | 9.4% | 1.8% | ||
| Q3 24 | 2.2% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 1.63× | ||
| Q3 25 | — | 1.59× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
IEX
Segment breakdown not available.
